Serum fibroblast growth factor 21 and new-onset metabolic syndrome: KoGES-ARIRANG study

Jung Ran Choi, Jang Young Kim, Il Hwan Park, Ji Hye Huh, Ki Woo Kim, Seung Kuy Cha, Kyu Sang Park, Joon Hyung Sohn, Jong Taek Park, Sang Baek Koh

Research output: Contribution to journalArticle

6 Citations (Scopus)


Purpose: Fibroblast growth factor 21 (FGF21) is a crucial metabolic regulator, with multiple favorable effects on glucose homeo-stasis and lipid metabolism. Since serum FGF21 level has been implicated as a potential marker for the early identification of metabolic syndrome (MetS), we investigated the association between serum FGF21 level and the development of MetS in a population-based prospective study. Materials and Methods: We conducted a prospective study of 221 randomly sampled adults without MetS from a general population-based cohort study who were examined from 2005–2008 (baseline) and from 2008–2011 (follow-up). Baseline serum FGF21 levels were analyzed using enzyme-linked immunosorbent assay. Results: During the average 2.8-year follow-up period, 82 participants (36.6%) developed new-onset MetS. Serum FGF21 levels were significantly higher in patients with new-onset MetS than in those without MetS (209.56±226.80 vs. 110.09±81.10, p<0.01). In multivariate adjusted models, the odds for MetS development were greater in patients with serum FGF21 levels in the highest quartile, compared to those in the lowest quartile (3.84, 95% confidence interval: 1.59–9.28). Conclusion: Serum FGF21 level was an independent predictor for new-onset MetS in a population-based prospective study.

Original languageEnglish
Pages (from-to)287-293
Number of pages7
JournalYonsei medical journal
Issue number2
Publication statusPublished - 2018 Mar

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Fingerprint Dive into the research topics of 'Serum fibroblast growth factor 21 and new-onset metabolic syndrome: KoGES-ARIRANG study'. Together they form a unique fingerprint.

  • Cite this